Federal Register #E2142024

NCI Offers Licensing and Co-Development for CARs Targeting Gamma Delta T-Cell Receptor

The National Cancer Institute (NCI), part of the National Institutes of Health under the Department of Health and Human Services, is offering a government-owned invention for license and research co-development: - Government Buyer: - Department of Health and Human Services - National Institutes of Health - National Cancer Institute - Technology Offered: - Chimeric Antigen Receptors (CARs) targeting the gamma delta (γδ) T-Cell Receptor - Developed by NCI researchers (no commercial OEMs or vendors named) - Pre-clinical stage with in vivo validation - Patent application PCT/US2025/040252 (NIH Reference Number E2142024) - Intended Applications: - Oncology: treatment of aggressive γδ T-cell cancers - Immunology: potential for autoimmune diseases involving γδ T cells - Unique/Notable Requirements: - Opportunity is for technology licensing or research co-development, not product procurement - Enables GMP production of personalized T cell therapy products - Focus on improved therapeutic benefit and enhanced manufacturing processes - No specific product part numbers or purchase quantities, as this is a technology transfer/licensing opportunity

Description

The National Cancer Institute (NCI) is seeking research co-development partners and/or licensees for a set of Chimeric Antigen Receptors (CARs) that target the gamma delta (γδ) T-Cell Receptor. These CARs can specifically bind to and immunologically recognize human γδ TCR, eliciting an immune response to kill cells expressing this receptor. The technology is aimed at treating aggressive cancers and autoimmune diseases involving γδ T cells. The invention is at the pre-clinical stage with in vivo validation and offers potential for personalized T cell therapy products with enhanced therapeutic benefits.

View original listing